Switzerland approves vaccine that targets two Covid variants
Moderna's new Covid-19 vaccine has been given temporary approval in Switzerland.
Copyright 2022 The Associated Press. All Rights Reserved
The Swiss medicaments regulator Swissmedic has given temporary approval for a Covid-19 vaccine from Moderna that has been adapted to give protection against two different strains of the virus.
This content was published on
1 minute
swissinfo.ch/mga
Español
es
Suiza aprueba vacuna contra dos variantes de COVID
The ‘Spikevax Bivalent Original/Omicron’ is designed to be administered in two 0.5ml doses.
It contains 25 micrograms of the original Spikevax mRNA-1273 plus 25 micrograms of a different mRNA that targets the Omicron variant (BA.1 and BA.4/5).
On Monday, Swissmedic saidExternal link that in trials the dual vaccine had achieved higher antibody concentrations against the Omicron variant than the original Spikevax, “with comparable side-effects”.
Those side-effects can include irritation, redness or swelling at the injection site, fatigue, headache, chills or nausea.
The Human Medicines Expert Committee has also given its separate seal of approval for the new vaccine, said Swissmedic.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
Should Switzerland take measures to support its struggling industries?
Industrial policies are back in fashion, not only in the United States but also in the EU. Should Switzerland, where various industries are struggling, draw inspiration from such policies?
As a Swiss Abroad, how do you feel about the emergence of more conservative family policies in some US states?
In recent years several US states have adopted more conservative policies on family issues, abortion and education. As a Swiss citizen living there, how do you view this development?
Swiss authorities file criminal complaint for false signatures
This content was published on
The case of allegedly forged signatures for popular initiatives in Switzerland continues: the Federal Chancellery has filed a criminal complaint for the third time.
Swiss government must prioritise transport projects
This content was published on
Following the no to motorway expansions and additional costs for future rail infrastructure, the Swiss government must set priorities for road and rail expansion.
SMI back above 12,500 points for first time since beginning of 2022
This content was published on
The leading SMI index rose by almost 1% at times in the morning and traded above 12,500 points for the first time since the beginning of 2022.
Markus Ritter enters race for seat in Swiss government
This content was published on
Markus Ritter from the Centre Party has thrown his hat into the ring to succeed Defence Minister Viola Amherd on the seven-seat Swiss government.
Lausanne hospital produces drug from faecal bacteria
This content was published on
The University Hospital of canton Vaud (Chuv) is the first Swiss hospital to receive approval for the production of such drugs from donor stool.
Increase in heat deaths set to outweigh decrease in cold deaths
This content was published on
The growing number of heat-related deaths due to climate change will significantly exceed the decline in the number of cold-related deaths in Europe, according to a study.
Every second Swiss buys from Chinese online retailers
This content was published on
Chinese online retailers are becoming increasingly popular in Switzerland. Every other person has already made such a purchase in the past year.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Switzerland gives green light to Moderna’s Covid vaccine for 6-11 year olds
This content was published on
The Swiss medical regulator Swissmedic has approved Moderna’s Spikevax Covid-19 vaccine for use by children aged 6 to 11 years.
Switzerland approves its first protein-based Covid vaccine
This content was published on
The Swiss medical regulator has approved the Nuvaxovid vaccine for adults making it the fourth Covid-19 vaccine authorised in the country.
Too many Covid doses: Switzerland’s vaccine conundrum
This content was published on
Switzerland is sitting on around 38 million excess Covid-19 vaccine doses to be used by the end of 2022. What will it do with them?
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.